Gland Pharma Limited

rs 25

May 19, 2022 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 National Stock Exchange of India Limi

40%

ations (INR Mn) EBITDA (1) / EBITDA Margin (2) (INR Mn / %) 11,030 44,007 8,877 34,629 3,749 40% 4,136 35% 14,370 40% 17,341 37% Q4 FY21 Q4 FY22 FY21 FY22 Q4 FY21 Q4 FY22 FY21 FY22

35%

Mn) EBITDA (1) / EBITDA Margin (2) (INR Mn / %) 11,030 44,007 8,877 34,629 3,749 40% 4,136 35% 14,370 40% 17,341 37% Q4 FY21 Q4 FY22 FY21 FY22 Q4 FY21 Q4 FY22 FY21 FY22 PBT / PAT /

37%

argin (2) (INR Mn / %) 11,030 44,007 8,877 34,629 3,749 40% 4,136 35% 14,370 40% 17,341 37% Q4 FY21 Q4 FY22 FY21 FY22 Q4 FY21 Q4 FY22 FY21 FY22 PBT / PAT / PAT Margin (3) (INR Mn / %

28%

rgin (3) (INR Mn / %) R&D Expenses / (R&D % of Revenue) (INR Mn / %) 3,489 3,805 13,348 2,604 28% 29% 2,859 24% 28% 16,186 12,117 26% 9,970 28% 5.1% 559 116 4.0% 443 3.4% 304 2 3.4

29%

(3) (INR Mn / %) R&D Expenses / (R&D % of Revenue) (INR Mn / %) 3,489 3,805 13,348 2,604 28% 29% 2,859 24% 28% 16,186 12,117 26% 9,970 28% 5.1% 559 116 4.0% 443 3.4% 304 2 3.4% 30

24%

/ %) R&D Expenses / (R&D % of Revenue) (INR Mn / %) 3,489 3,805 13,348 2,604 28% 29% 2,859 24% 28% 16,186 12,117 26% 9,970 28% 5.1% 559 116 4.0% 443 3.4% 304 2 3.4% 302 5.2% 2,2

26%

% of Revenue) (INR Mn / %) 3,489 3,805 13,348 2,604 28% 29% 2,859 24% 28% 16,186 12,117 26% 9,970 28% 5.1% 559 116 4.0% 443 3.4% 304 2 3.4% 302 5.2% 2,273 342 1,932 4.4% 3.5%

5.1%

R Mn / %) 3,489 3,805 13,348 2,604 28% 29% 2,859 24% 28% 16,186 12,117 26% 9,970 28% 5.1% 559 116 4.0% 443 3.4% 304 2 3.4% 302 5.2% 2,273 342 1,932 4.4% 3.5% 1,220 21 1,199

4.0%

3,805 13,348 2,604 28% 29% 2,859 24% 28% 16,186 12,117 26% 9,970 28% 5.1% 559 116 4.0% 443 3.4% 304 2 3.4% 302 5.2% 2,273 342 1,932 4.4% 3.5% 1,220 21 1,199 3.4% Q4 FY21

3.4%

,348 2,604 28% 29% 2,859 24% 28% 16,186 12,117 26% 9,970 28% 5.1% 559 116 4.0% 443 3.4% 304 2 3.4% 302 5.2% 2,273 342 1,932 4.4% 3.5% 1,220 21 1,199 3.4% Q4 FY21 Q4 FY22 F

5.2%

,859 24% 28% 16,186 12,117 26% 9,970 28% 5.1% 559 116 4.0% 443 3.4% 304 2 3.4% 302 5.2% 2,273 342 1,932 4.4% 3.5% 1,220 21 1,199 3.4% Q4 FY21 Q4 FY22 FY21 FY22 Q4 FY21 Q4 F

Delivery Systems

1

Therapeutic Areas

1

Present in

1

Focused on

1

Corporate Office

1

Therapeutic Areas

• Anti-diabetic • Neurological and Central • Anti-infectives • Anti-malarials • Anti-neoplastics (Oncology) • Blood-related • Cardiac • Gastro-intestinal • Hormones Nervous System • Ophthalmics and Otologicals • Pain, neuro-muscular blocking agents & analgesics • Respiratory • Vitamins, minerals & nutrients Centralized R&D Laboratory located at Dundigal, Hyderabad facility, with supporting personnel at each manufacturing facility ~315 personnel team including PhDs, pharmacy post graduates and chemists New R&D building at Pashamylaram, Hyderabad R&D expertise supports regulatory filings globally Regulatory Track Record • 311 ANDA Filings in US – 252 approved; 59 pending (1) ̶ Of 311, 139 owned by Gland Pharma out of which 100 are approved and 39 are pending for approval 227 for sterile injectables, 54 for oncology and 30 for ophthalmics related products • 1,557 product registrations globally, of which 418 in United States, Europe, Canada and Australia, 69 in India and 1070 in Rest of th

Present in

 Oncology  Ophthalmics and Otologicals  Blood-related  Neurological and Central Nervous System  Pain, neuro-muscular agents and analgesics

Focused on

 Complex injectables  NCE-1s  First-to-File products Expanding capabilities in: Expanding in new delivery systems: Key products include:  Peptides  Pens  Long-acting injectables  Suspensions  Cartridges  Cis-Atracurium Besylate  Enoxaparin Sodium  Heparin Sodium  Rocuronium Bromide  505(b)(2) filings  Hormonal products  Biosimilar Significant R&D Investment Translating into Revenue From New Launches Centralized R&D team of c.315 members including PhDs, pharmacy post graduates and chemists Track record of coming up with new complex products 3.8% 4.7% 3.5% 3.5% 5.2% 2,273 615 966 922 1,220 22% 13% 9% 11% 5% 58 3,493 45 2,717 51 2,292 52 3,660 44 2,360 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Total R&D expenditure (₹mn) Revenue from new product launch (₹mn) R&D expenditure as % of revenue from operations As % of revenue from operations # products launched 25 …Supported by Proven Regulatory Capabilities Product Development Capabilities Supported by Regulatory Expert

Corporate Office

Gland Pharma Limited Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India 543245 GLAND GLAND:IN 34